Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
Serapha Bio and Boundless Bio Announce Merger and $230 Million Private Placement
Gibson Dunn has advised Serapha Bio, Inc. Latham & Watkins has advised Boundless Bio, Inc. Serapha Bio, Inc., a privately held biotechnology company, and Boundless Bio,...
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering
Latham & Watkins LLP has advised Mineralys Therapeutics. Cleary Gottlieb has represented the underwriters, including BofA Securities Inc., Goldman Sachs & Co. LLC, and Evercore Group...
Vaxcyte Completes $632.5 Million Public Offering of Common Stock
Skadden has advised Vaxcyte, Inc. Latham & Watkins LLP has advised the underwriters. Vaxcyte, Inc. has completed the closing of an underwritten public offering of 12,650,000...
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing
Mintz has advised Satellos Bioscience Inc. Latham & Watkins has represented the underwriters. Satellos Bioscience Inc., a clinical-stage biotechnology company, has completed a US$57.2 million underwritten...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
Boston Scientific’s Acquisition of SoniVie Ltd.
Latham & Watkins advised Boston Scientific, while K&L Gates advised SoniVie Ltd. on the transaction. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie
Latham & Watkins advised AbbVie on the transaction, and Ropes & Gray advised Xilio Therapeutics. Xilio Therapeutics (Nasdaq: XLO) announced a strategic collaboration and option agreement...
Verona Pharma’s $650 Million Financing Round
Sidley Austin represented OMERS Life Sciences in the transaction, while Latham & Watkins advised Verona Pharma and Sullivan & Cromwell represented Oaktree Capital Management, L.P. Verona...
Advanced Micro Devices (AMD)’s $4.9 Billion Acquisition Of ZT Systems
Latham & Watkins advised Advanced Micro Devices – AMD on the acquisition Of ZT Systems advised by Paul Weiss. AMD (NASDAQ: AMD) signed a definitive agreement...
scPharmaceuticals’ $125 Million Senior Secured Term Loan
Latham & Watkins advised scPharmaceuticals on the deal. scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...